Abstract CT150: Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib (ATG-008) in HBV+ advanced hepatocellular carcinoma (HCC) subjects who have received at least one prior line of systemic therapy (TORCH)
Qin, Shukui, Lin, Xiaoyan, Meng, Zhiqaing, Ren, Zhenggang, Bai, Yuxian, Gu, Shanzhi, Zheng, Li, Li, Qiu, Oh, Sun-Yong, Guo, Yabing, Kang, Yoong-Koo, Kao, Wei-Yu, Li, Wei, Yoon, Jung-Hwan, Zhang, Helong, Chen, Pei-Jer, Yang, Tsai-Sheng, Heo, Jeong, Zheng, Zhendong, Xie, Hui, Yu, Zhinuan
Published in Cancer research (Chicago, Ill.) (14.04.2023)
Published in Cancer research (Chicago, Ill.) (14.04.2023)
Get full text
Journal Article